Zobrazeno 1 - 10
of 211
pro vyhledávání: '"Sven de Vos"'
Autor:
Anna Sureda, Lorenzo Falchi, Sirpa Leppa, Joost Vermaat, Harald Holte, Martin Hutchings, Pieternella Lugtenburg, Sven de Vos, Pau Abrisqueta, Marcel Nijland, Reid W. Merryman, Jacob Haaber Christensen, Bjorn Wahlin, Kim Linton, Liwei Wang, Aqeel Abbas, Ali Rana, Syed Quadri, David Belada
Publikováno v:
HemaSphere, Vol 7, p e5547136 (2023)
Externí odkaz:
https://doaj.org/article/327f7aeaa4ac4754846a26ed47c7ba62
Autor:
Michael Roost Clausen, David Belada, Fritz Offner, Sven de Vos, Joshua Brody, Kim Linton, Sylvia Snauwaert, Raul Cordoba, Jun Wu, Irina Bykhovski, Liwei Wang, Ali Rana, Lorenzo Falchi
Publikováno v:
HemaSphere, Vol 7, p e55140cd (2023)
Externí odkaz:
https://doaj.org/article/60cb36dc2c9040eeab31847d55e92ef0
Autor:
Javier Munoz, Frederick Locke, Lazaros Lekakis, Herbert Eradat, Michael Tees, Sven de Vos, Rajneesh Nath, Don Stevens, Shahbaz Malik, Leslie Popplewell, Mehdi Hamadani, Olalekan Oluwole, Miguel-Angel Perales, David Miklos, Paul Fisher, Lovely Goyal, Lynn Navale, Gregory Kaufman, Kazuharu Kai, Arun Balakumaran, Sattva Neelapu
Publikováno v:
HemaSphere, Vol 7, p e8808264 (2023)
Externí odkaz:
https://doaj.org/article/862aabdc556345c085b2dd16ce99e9bc
Autor:
Stephen Spurgeon, Matthew Mei, Paul M. Barr, Jacqueline Barrientos, Sven de Vos, Richard Furman, Krish Patel, Philip Thompson, Michael Y. Choi, Avyakta Kallam, Siruo Wang, Uzor Ogbu, Patricia Marinello, Michael Wang
Publikováno v:
HemaSphere, Vol 7, p e54506b2 (2023)
Externí odkaz:
https://doaj.org/article/2376d173237d400ba7d058b36755fbeb
Autor:
Radhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, Jia Ruan, Kirit M. Ardeshna, Roderick Johnson, Gregor Verhoef, David Cunningham, Sven de Vos, Shireen Kassam, Luis Fayad, John Radford, Sarah Bailly, Fritz Offner, David Morgan, Javier Munoz, Jerry Ping, Edith Szafer-Glusman, Karl Eckert, Jutta K. Neuenburg, Andre Goy
Publikováno v:
EClinicalMedicine, Vol 56, Iss , Pp 101779- (2023)
Summary: Background: This phase 1b/2 PCYC-1123-CA study evaluated efficacy and safety of the combination of ibrutinib, lenalidomide, and rituximab (iR2 regimen) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) ineligible for
Externí odkaz:
https://doaj.org/article/dfd82da8bbb84527a2f321cc93dfec23
Autor:
Patrick B. Johnston, Amanda F. Cashen, Petros G. Nikolinakos, Anne W. Beaven, Stefan Klaus Barta, Gajanan Bhat, Steven J. Hasal, Sven De Vos, Yasuhiro Oki, Changchun Deng, Francine M. Foss
Publikováno v:
Experimental Hematology & Oncology, Vol 10, Iss 1, Pp 1-11 (2021)
Abstract Background Belinostat is a histone deacetylase inhibitor approved for relapsed refractory peripheral T-cell lymphoma (PTCL). The primary objective of this study was to determine the maximum tolerated dose (MTD) of belinostat combined with CH
Externí odkaz:
https://doaj.org/article/af527152ded04cb9a0629860f5f6b4cf
Autor:
Johannes Duell, Kami J. Maddocks, Eva González-Barca, Wojciech Jurczak, Anna Marina Liberati, Sven de Vos, Zsolt Nagy, Aleš Obr, Gianluca Gaidano, Pau Abrisqueta, Nagesh Kalakonda, Marc André, Martin Dreyling, Tobias Menne, Olivier Tournilhac, Marinela Augustin, Andreas Rosenwald, Maren Dirnberger-Hertweck, Johannes Weirather, Sumeet Ambarkhane, Gilles Salles
Publikováno v:
Haematologica, Vol 999, Iss 1 (2021)
Not available.
Externí odkaz:
https://doaj.org/article/87ddd8a6674b4a1a85c63967777aba9a
Autor:
Paolo Strati, Sven de Vos, Jia Ruan, Kami J. Maddocks, Christopher R. Flowers, Simon Rule, Priti Patel, Yan Xu, Helen Wei, Melanie M. Frigault, Roser Calvo, Martin J.S. Dyer
Publikováno v:
Haematologica, Vol 106, Iss 10 (2021)
Externí odkaz:
https://doaj.org/article/307471bf81fb484f9a57ab90161ef810
Publikováno v:
Leukemia Research Reports, Vol 16, Iss , Pp 100260- (2021)
Tafasitamab (MOR208) is an Fc-enhanced, humanized, monoclonal antibody that targets CD19. The L-MIND (NCT02399085) trial, an open-label, single-arm, phase II study of Tafasitamab (TAFA) plus lenalidomide (LEN), reported progression-free survival of 1
Externí odkaz:
https://doaj.org/article/94a0208d3c074e2d91604c262a5bd363
Autor:
Sven de Vos, Nina D. Wagner-Johnston, Steven E. Coutre, Ian W. Flinn, Marshall T. Schreeder, Nathan H. Fowler, Jeff P. Sharman, Ralph V. Boccia, Jacqueline C. Barrientos, Kanti R. Rai, Thomas E. Boyd, Richard R. Furman, Yeonhee Kim, Wayne R. Godfrey, John P. Leonard
Publikováno v:
Blood Advances, Vol 1, Iss 2, Pp 122-131 (2016)
Abstract: Idelalisib, a first-in-class oral inhibitor of phosphatidylinositol-3-kinase δ, has shown considerable antitumor activity as a monotherapy in recurrent indolent non-Hodgkin lymphoma (iNHL). To evaluate the safety and activity of idelalisib
Externí odkaz:
https://doaj.org/article/fc19ab6357334e8a83fbb5997926325c